Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Monotherapy, Combo Data Outshine Amgen’s Lumakras
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
You may also be interested in...
Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
Amgen NSCLC Data Could Give Lumakras Boost As Competition Looms
Mirati’s adagrasib is expected to win an FDA lung cancer nod, while also showing better data in pancreatic and colorectal cancer, making it more important for Lumakras to show strength in NSCLC.
Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data
The biotech also provided an update on its pursuit of approval for adagrasib, a KRAS G12C inhibitor that is likely to compete against Amgen’s first-to-market Lumakras.